Cancer Research UK's drug development office (DDO) has entered into a strategic combinations alliance with AstraZeneca to move combinations of experimental cancer drugs into early phase clinical trials.
The collaboration will enable more patients to participate in trials of potential new cancer treatments that combine molecularly targeted experimental drugs developed and owned by AstraZeneca.
The trials will also evaluate these combinations along with conventional chemotherapy radiotherapy and other novel agents.
The trials will be managed and conducted through the Cancer Research UK/ UK Health Departments Experimental Cancer Medicine Centre (ECMC) Network at hospitals across the UK, while Cancer Research UK’s Drug Development Office will provide support for the trials.
AstraZeneca will provide access to its drugs to be evaluated through the alliance as well as additional financial support.
Cancer Research UK’s DDO head of the combinations alliance Kate Miller said the firm is delighted to be collaborating with AstraZeneca through the combinations alliance.
"This initiative will provide a huge boost to the UK research community in developing exciting new combination therapies and will mean that more UK patients will be able to take part in important clinical trials of potential new treatments," Miller said.